These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16118228)

  • 41. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
    Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
    Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?
    Berthelot JM; Tortellier L; Lavy-Bregeon D; Le Goff B; Maugars Y
    Joint Bone Spine; 2008 Mar; 75(2):167-71. PubMed ID: 18296097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
    Machado P; Landewé RB; Braun J; Baraliakos X; Hermann KG; Hsu B; Baker D; van der Heijde D
    Ann Rheum Dis; 2012 Dec; 71(12):2002-5. PubMed ID: 22915615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study.
    Krzysiek R; Breban M; Ravaud P; Prejean MV; Wijdenes J; Roy C; Henry YD; Barbey C; Trappe G; Dougados M; Emilie D;
    Arthritis Rheum; 2009 May; 61(5):569-76. PubMed ID: 19405015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
    Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
    Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
    Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
    Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
    [No Abstract]   [Full Text] [Related]  

  • 49. The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.
    Troppmann L; Karsh J;
    J Rheumatol; 2008 Apr; 35(4):658-61. PubMed ID: 18278833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
    J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
    Keeling S; Oswald A; Russell AS; Maksymowych WP
    J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
    van Denderen JC; van der Horst-Bruinsma I; Bezemer PD; Dijkmans BA
    J Rheumatol; 2003 Jul; 30(7):1558-60. PubMed ID: 12858458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.
    Lin Z; Gu J; He P; Gao J; Zuo X; Ye Z; Shao F; Zhan F; Lin J; Li L; Wei Y; Xu M; Liao Z; Lin Q
    Rheumatol Int; 2011 Feb; 31(2):233-8. PubMed ID: 20012866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass.
    Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S
    Platelets; 2010; 21(2):126-31. PubMed ID: 20050759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study.
    Salvarani C; Cantini F; Niccoli L; Catanoso MG; Macchioni P; Pulsatelli L; Padula A; Olivieri I; Boiardi L
    J Rheumatol; 2003 Apr; 30(4):760-3. PubMed ID: 12672196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.